Articles
Breast cancer is the second most common cancer among women after skin cancer, according to the National Cancer Institute. In fact, in 2024 an estimated 310,720 cases will be diagnosed in women, representing 15.5% of all new cancers diagnosed that year, and 42,250 women with breast cancer will die. Test your knowledge of this widespread cancer. Read More ›
Approximately 40% of American men and women will be diagnosed with cancer at some point in their lives,1 with the cost of cancer care in the United States projected to exceed $245 billion by 2030.2 Read More ›
By Colleen Hall
While the panel acknowledged there is a long way to go in terms of encouraging diverse patient populations to participate in clinical trials, they note that there is reason for hope. Before the draft guidance was even issued by the FDA in June, several industry sponsors had already partnered with health care professionals to boost clinical trial participation. Read More ›
Much progress has been made in the past 50 years since the signing of the National Cancer Act of 1971, which included the establishment of the President’s Cancer Panel. Nevertheless, there remain significant opportunities to make improvements across the cancer spectrum, perhaps none more pressing than in the realm of prevention and early detection. Read More ›
Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP, discusses updated data from the phase 1a/1b trial of zongertinib in patients with HER2 aberration-positive solid tumors. In this video, she reports data from phase 1b, the ongoing dose expansion phase, which includes patients with HER2 mutation–positive NSCLC and focuses on nursing considerations for managing adverse events. Read More ›
Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP, discusses the trial design of Beamion LUNG-2, a randomized phase 3 trial of zongertinib versus standard of care in patients with locally advanced or metastatic NSCLC harboring HER2 tyrosine kinase domain (TKD) mutations. She discusses the role of nurses in clinical trials, including providing essential monitoring and support to patients during their trial participation. Read More ›
Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP, discusses results from an exposure-efficacy and exposure-safety analysis of trastuzumab deruxtecan in patients with HER2-mutated NSCLC. In her recap, she highlights the importance of education around dose adjustments to manage patient expectations. Read More ›
Final results from the randomized phase 2 trial of trastuzumab deruxtecan in patients with HER2-mutant NSCLC were reported at ASCO 2024 and summarized in this video by Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP. She recaps the efficacy and safety data while highlighting the importance of nurses in assessing and managing adverse events associated with these medications. Read More ›
The Oncology Pharmacist is dedicated to providing comprehensive information aimed at eliminating health disparities and improving access to therapies for people from all populations, including racial and ethnic minorities; people with limited access to healthcare due to lack of financial resources; and people living in rural communities. Read More ›
The National Cancer Institute invests in a broad portfolio of research, supporting the cancer research workforce and sustaining the infrastructure that enables cutting-edge research to succeed. These efforts are essential to lead progress against cancer and accomplish the goals of the National Cancer Plan. Read More ›